



ASX / Media Release  
22 December 2023

## Invex and Peptron Mutually Terminate Manufacturing Agreement

---

**Invex Therapeutics Ltd (Invex, ASX:IXC, or the Company)** a biopharmaceutical company focused on the development and commercialisation of Exenatide for neurological conditions relating to raised intracranial pressure today announces the mutual termination of the long term Collaboration and Manufacturing Agreement with Peptron, Inc. (KOSDAQ: 087010), a biopharmaceutical company developing sustained-release peptide-based medicines with high technological barriers to treat chronic diseases, based in Daejeon, Korea.

As part of the termination, Peptron and Invex will waive a reciprocal regulatory fee that was payable upon each party receiving an initial Investigational New Drug (IND) application with the US Food and Drug Administration. Invex was awarded an IND by the FDA for the IIH EVOLVE Phase III trial on 18 August 2022. Invex will provide to Peptron certain regulatory documents associated with the IIH EVOLVE trial and Invex has granted Peptron an exclusive, royalty-free license to commercialise Presendin™ for Idiopathic Intracranial Hypertension (IIH) in Korea and China. In addition, Peptron has been granted a first right of refusal for global development rights in IIH.

Dr Thomas Duthy, Executive Director of Invex Therapeutics commented “With the closure of the IIH EVOLVE clinical trial, there was no longer a need for Invex to order additional finished drug product and placebo from Peptron to support our global study in IIH. For our traumatic brain injury and glaucoma activities, Peptron’s sustained release formulation of Exenatide is not considered an appropriate formulation. Accordingly, Invex and Peptron have agreed to mutually terminate the Collaboration and Manufacturing Agreement signed in September 2021 with immediate effect.”

- ENDS -

*This release dated 22 December 2023 has been authorised for lodgement to ASX by the Board of Directors of Invex Therapeutics.*

---

### For more information, please contact:

#### Company/Investors

Dr Thomas Duthy  
Executive Director  
[tduthy@invextherapeutics.com](mailto:tduthy@invextherapeutics.com)  
+61 402 493 727

#### Media

Margie Livingston  
Ignite Communications  
[margie@ignitecommunications.com.au](mailto:margie@ignitecommunications.com.au)  
+61 438 661 131

To subscribe to Invex email alerts, please visit [www.invextherapeutics.com](http://www.invextherapeutics.com) and follow us on Twitter @InvexThera\_ASX

## About Invex Therapeutics Ltd

---

Invex is a biopharmaceutical company focused on the repurposing of an already approved drug, Exenatide, for efficacious treatment of neurological conditions derived from or involving raised intracranial pressure. Invex has trademarked its repurposed Exenatide as Presendin™. [www.invextherapeutics.com](http://www.invextherapeutics.com).

For personal use only